Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment

The COVID-19 pandemia is affecting people worldwide. Most of the patients suffered of a respiratory disease that will progress to an acute respiratory distress syndrome (ARDS). SARS-CoV-2 pneumonia severely ill patients, develop a systemic inflammatory response with a Cytokine Release Syndrome (CRS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lara, Pedro C., Burgos, Javier, Macias, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193092/
https://www.ncbi.nlm.nih.gov/pubmed/32373721
http://dx.doi.org/10.1016/j.ctro.2020.04.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193092/
https://www.ncbi.nlm.nih.gov/pubmed/32373721
http://dx.doi.org/10.1016/j.ctro.2020.04.006

Ejemplares similares